Anzeige
Mehr »
Login
Dienstag, 03.08.2021 Börsentäglich über 12.000 News von 667 internationalen Medien
Es wird ernst: Die richtig große Kurswette für KW 31
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J84E ISIN: US00287Y1091 Ticker-Symbol: 4AB 
Tradegate
02.08.21
21:59 Uhr
97,50 Euro
-0,50
-0,51 %
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
ABBVIE INC Chart 1 Jahr
5-Tage-Chart
ABBVIE INC 5-Tage-Chart
RealtimeGeldBriefZeit
97,3997,7902.08.
96,9697,5402.08.

Aktuelle News zur ABBVIE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoFTC Drops Antitrust Case Against AbbVie5
MoAbbVie Inc. - 10-Q, Quaterly Report5
MoTakeda still on the hook for €398M tax linked to distant AbbVie-Shire breakup fee6
ABBVIE Aktie jetzt für 0€ handeln
MoFTC drops antitrust case against AbbVie, but still decries the company's 'ill-gotten gains'8
MoFTC pulls remaining case against AbbVie; New EU clinical trials system coming in 2022; Abingworth bets big on CymaBay5
Mo€398M Irish tax decision on Takeda upheld on Shire/Abbvie break fee9
MoAbbvie - Still Undervalued With More Room To Grow24
FrAbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2021 Results - Earnings Call Transcript29
FrFTC drops antitrust complaint against AbbVie after Supreme Court declines case review17
FrAbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic12
FrAbbVie's post-Humira stalwarts Skyrizi, Rinvoq performing exactly as hoped, CEO says16
FrAbbVie Edges Past Views With Stock Right At Buy Point12
FrBeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win9
FrAbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised25
FrAbbvie to advance beta-amyloid Alzheimer's candidate, abandons tau asset7
FrAbbVie, riding the Aduhelm afterglow, handpicks beta amyloid drug for further R&D as it bails on tau3
FrAbbVie Inc. Reports Second-Quarter 2021 Financial Results23
FrAbbVie Boosts Full-Year Guidance as Sales Rebound From Pandemic19
FrAbbVie Lifts FY Adj. Profit View381WASHINGTON (dpa-AFX) - AbbVie (ABBV) raised its adjusted earnings per share outlook for the full-year 2021 to a range of $12.52 - $12.62 from the prior outlook of $12.37 to $12.57 per share....
► Artikel lesen
FrAbbVie tops Q2 forecast; non-GAAP EPS outlook for FY21 raised12
Seite:  Weiter >>
416 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
6,4,42